Owlet Inc Stock Price, News & Analysis

Owlet (NYSE: OWLT) launched Owlet360 in the UK and Ireland on December 10, 2025, a subscription service that delivers personalized sleep and health insights for families using Dream Sock, Dream Sight or Owlet Cam 2.

Core live vital monitoring and real-time notifications remain free. Owlet360 leverages a dataset from more than 2.5 million babies and follows rapid U.S. adoption of over 90,000 subscribers. The service is available now with monthly or yearly plans and a seven-day free trial for eligible users.

Owlet (NYSE: OWLT) announced on December 5, 2025 that its Dream Sock has received TGA approval and is now available in Australia and New Zealand via Owlet websites and select retail partners. The launch includes the first international rollout of the Owlet360 subscription, extending the Company’s recurring-revenue platform.

Dream Sock is a clinically validated wearable for infants 0–18 months (2.5–13.6 kg) that tracks pulse rate, oxygen level, and sleep trends with real-time alerts via the Owlet Dream App and Base Station. Owlet360 adds personalized guidance, expert resources, daily sleep reports, and expanded trend analytics above the app’s free core tracking.

Owlet (NYSE: OWLT) was named to Fast Company’s 2025 Brands That Matter list on December 2, 2025, recognizing brands that achieve cultural significance and deep customer connection.

Owlet highlighted its human-centered mission, the first and only FDA-cleared baby monitor, a growing ecosystem of connected products, partnerships with more than 40 global nonprofits, and over $2.5M donated in product and charitable support.

The recognition emphasizes Owlet’s brand storytelling, community engagement, and reach among millions of parents worldwide as it seeks to expand into underserved markets.

Owlet (NYSE: OWLT) selected OpenSynergy's Blue SDK to provide Bluetooth® connectivity for its new Dream Sight camera baby monitor, aiming to improve connection stability, interoperability, and security across iOS and Android devices.

The Blue SDK is pre-qualified with the Bluetooth SIG, which Owlet says streamlined qualification and certification. Owlet highlighted faster development timelines, ongoing security monitoring by OpenSynergy, and broader Bluetooth feature support; Dream Sight is available now alongside Dream Sock and Dream Duo, and Owlet reports being trusted by over 2.5 million families in 30+ countries.

Owlet (NYSE: OWLT) announced a partnership with Locus Health on November 19, 2025 to integrate data from Owlet’s FDA-cleared BabySat prescription device into Locus Health’s remote patient monitoring platform. The integration delivers ongoing, secure access to infant vitals — including oxygen saturation and pulse rate — into clinicians’ existing workflows after hospital discharge.

This collaboration aims to improve continuity of care for infants leaving ICU, reduce manual data entry and transcription errors, and extend monitoring for complex conditions while leveraging Owlet’s scale (over 2.5 million babies monitored).

Owlet (NYSE:OWLT) reported record Q3 2025 results: revenue $32.0M (+44.6% YoY), gross profit $16.2M (gross margin 50.6%), operating income $1.2M and net income $4.1M$1.6M. Management cited tariff impacts that reduced gross margin by 150 basis points and noted strong international growth (~171% YoY) with an India regulatory clearance expected for early 2026. Owlet360 subscriptions surpassed 85,000 paying subscribers. Updated 2025 guidance: revenue $103M–$106M, gross margin 48%–50% (including tariffs), and adjusted EBITDA $1.25M–$2.0M. A warrant exchange and follow-on equity offering completed in October.

Owlet (NYSE: OWLT) announced a partnership with Rhapsody on November 12, 2025 to connect infant monitoring data from Owlet’s FDA-cleared prescription pulse oximeter, BabySat, into electronic health record (EHR) workflows.

The integration uses standards-based connectivity to send clinically validated infant vital signs into provider EHRs, aiming to reduce custom development, minimize errors, and allow clinicians to view continuous, real-time home-monitoring data within existing patient records. The partnership is positioned to support scaling pediatric remote patient monitoring programs and strengthen home-to-hospital data sharing.

Owlet (NYSE: OWLT) announced that its Dream Sight baby monitor is the first and only monitor to earn the SGS Cybersecurity Mark, after testing by Brightsight and EU Type Certification by SGS Fimko Oy under the European Radio Equipment Directive (RED) Articles 3(3)(d) and (e).

Launched in September 2025, Dream Sight features 2K HD streaming, night vision, motion/sound detection, two-way audio, and temperature/humidity tracking, and can integrate with the FDA-cleared Dream Sock for clinically validated vital signs and wellness trends.

Owlet (NYSE: OWLT) will report third quarter 2025 financial results after market close on Thursday, November 13, 2025. The company said President & CEO Jonathan Harris and CFO Amanda Twede Crawford will host a conference call at 4:30 p.m. ET the same day to discuss results and provide a business update.

Participants can join by phone at 833-470-1428 (domestic) or 646-844-6383 (international) using Access Code 428622. A simultaneous webcast and replay will be available in the Events section of Owlet's Investor Relations website at investors.owletcare.com.